INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 40 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $4,464,000 | +65.9% | 5,750,000 | +109.1% | 0.02% | +58.3% |
| Q2 2017 | $2,690,000 | +28.3% | 2,750,000 | +22.2% | 0.01% | +20.0% |
| Q1 2017 | $2,096,000 | +4.5% | 2,250,000 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $2,006,000 | – | 2,250,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Birch Grove Capital LP | 15,003,000 | $13,500,000 | 6.56% |
| PenderFund Capital Management Ltd. | 9,605,000 | $10,735,000 | 2.51% |
| Silver Point Capital L.P. | 38,808,000 | $34,151,000 | 1.87% |
| Benefit Street Partners LLC | 5,045,000 | $4,440,000 | 1.69% |
| Context Capital Management, LLC | 11,279 | $10,168,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $51,920,000 | 0.92% |
| DeepCurrents Investment Group LLC | 30,292,000 | $27,169,000 | 0.81% |
| Saltoro Capital, LP | 1,800,000 | $1,623,000 | 0.66% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 20,481,000 | $18,638,000 | 0.52% |
| Kohlberg Kravis Roberts & Co. L.P. | 64,548,000 | $58,191,000 | 0.24% |